Fig. 7

Irf6 is upregulated in breast tumor cells after neoadjuvant trastuzumab-based therapy. Formalin-fixed, paraffin-embedded tumor sections obtained from patients before and after the therapy were stained with an anti-Irf6 antibody. a Percentage of tumor cells with Irf6-positive nuclei before the treatment with neoadjuvant trastuzumab and after the treatment is shown. The data represent the average (plus the SE) of respective percentages observed in nine patients. b–e Representative samples obtained from patient 2 before (b, d) and after (c, e) the treatment are shown. The samples were stained with hematoxylin (blue) and eosin (red) (H&E) (b, c) or with an anti-Irf6 antibody (brown) and counterstained with hematoxylin (blue) (d, e)